Cellular immunity against viral infection and tumour cells depends on antigen presentation by major histocompatibility complex class I (MHC I) molecules. Intracellular antigenic peptides are transported into the endoplasmic reticulum by the transporter associated with antigen processing (TAP) and then loaded onto the nascent MHC I molecules, which are exported to the cell surface and present peptides to the immune system 1 . Cytotoxic T lymphocytes recognize non-self peptides and program the infected or malignant cells for apoptosis. Defects in TAP account for immunodeficiency and tumour development. To escape immune surveillance, some viruses have evolved strategies either to downregulate TAP expression or directly inhibit TAP activity. So far, neither the architecture of TAP nor the mechanism of viral inhibition has been elucidated at the structural level. Here we describe the cryo-electron microscopy structure of human TAP in complex with its inhibitor ICP47, a small protein produced by the herpes simplex virus I. Here we show that the 12 transmembrane helices and 2 cytosolic nucleotide-binding domains of the transporter adopt an inward-facing conformation with the two nucleotide-binding domains separated. The viral inhibitor ICP47 forms a long helical hairpin, which plugs the translocation pathway of TAP from the cytoplasmic side. Association of ICP47 precludes substrate binding and prevents nucleotide-binding domain closure necessary for ATP hydrolysis. This work illustrates a striking example of immune evasion by persistent viruses. By blocking viral antigens from entering the endoplasmic reticulum, herpes simplex virus is hidden from cytotoxic T lymphocytes, which may contribute to establishing a lifelong infection in the host.
Inside our body, every nucleated cell has surface 'barcodes' that are surveyed by the immune system. These barcodes are peptides derived from intracellular proteins, presented on the surface by MHC I molecules to indicate whether the cell is healthy (reviewed in ref. 1). Peptides generated from normal cellular proteins are ignored by cytotoxic T cells, whereas viral-derived or malignant peptides will trigger an adaptive immune response, resulting in elimination of the infected or tumour cells. The peptide repertoire is generated in the cytoplasm, mainly by the proteasome, but also in part by cytosolic peptidases (Fig. 1a ). Peptide uploading onto MHC I molecules takes place inside the endoplasmic reticulum (ER) and is orchestrated by a macromolecular assembly collectively called the MHC class I peptide-loading complex (PLC). Cytosolic peptides are delivered across the ER membrane by the ATP-binding cassette (ABC) transporter TAP. The chaperones calnexin and calreticulin stabilize nascent MHC I molecules awaiting peptides. The tapasin/ERp57 heterodimer brings MHC I molecules and TAP within close proximity and catalyses peptide loading. Peptide-loaded MHC I molecules are then released from the ER and transported to the cell surface for antigen presentation.
As the MHC I antigen presentation pathway plays a crucial role in eradicating intracellular pathogens, it is not surprising that some viruses have evolved the ability to interfere with this process (reviewed in ref. 2). The peptide transporter TAP in particular is a primary target for viral evasion (reviewed in ref.
3). TAP is a heterodimeric ABC transporter that contains two subunits, TAP1 and TAP2, which share 37% sequence identity and are predicted to have similar structures. Each subunit contains an amino (N)-terminal 
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transmembrane region (TMD0) that interacts with tapasin, followed by six transmembrane (TM) helices that form the peptide translocation pathway and a canonical nucleotide-binding domain (NBD) that hydrolyses ATP ( Fig. 1b ) 4 . The core TAP, devoid of the TMD0s, is necessary and sufficient for peptide transport 4 . So far, five viral proteins have been identified as TAP inhibitors. Four are encoded by members of the herpes virus family and one by cowpox virus 3 . These viral inhibitors are valuable tools for selective immune suppression and for understanding the fundamental mechanism of antigen presentation.
Here we focus our study on a TAP inhibitor encoded by herpes simplex virus (HSV). Both types of HSV, HSV-1 (oral herpes) and HSV-2 (genital herpes), somehow elude the human immune system and lead to a lifelong infection. The first clue as to how HSV bypasses the immune system came from observations that cells infected by HSV have reduced surface expression of MHC I molecules 5 and are resistant to cytotoxic T cells 6 . Since this resistance develops within 3 hours of HSV infection, researchers narrowed their search for the responsible gene to those few expressed in the early stage of infection 7,8 . Out of these, an 88-residue protein, ICP47, was found to bind to TAP and prevent peptide translocation into the ER 7,8 . Consequently, empty MHC I molecules were retained in the ER and viral peptide presentation was suppressed. Subsequent studies have shown that ICP47 interacts with TAP from the cytosolic side of the membrane and somehow prevents peptide binding 9,10 . The functional domain of ICP47 has been mapped to the N-terminal 35 residues 11,12 , which form an extended helix-loophelix structure in lipid bilayers 13 .
In this study, we pursued structural determination of a TAP-ICP47 complex using cryo-electron microscopy (cryo-EM). The small size of the complex (166 kDa total) and the predicted pseudo-twofold symmetry between TAP1 and TAP2 make it extremely challenging to accurately align particles for three-dimensional reconstruction. To maximize the difference between the two TAP subunits, we used LETTER RESEARCH a shorter allele of TAP2 that lacks the last 17 amino acids in NBD2 ( Fig. 1b) 14 . Co-expression of TAP1 and TAP2 in Pichia pastoris (Extended Data Fig. 1 ) produced a heterodimer that dissociates readily in detergents. However, by incubating the TAP-enriched membranes with ICP47 before detergent solubilization, the complex consisting of TAP1, TAP2, and ICP47 becomes more stable (Fig. 1c, d ). Cryo-EM analysis of this complex (Extended Data Fig. 2 and Fig. 1d ) produced a density map (Fig. 2) of an overall resolution of 6.5 Å, determined by the gold-standard refinement procedure (Extended Data Fig. 3) 15 . In this reconstruction the TM helices and the connectivity between the helices are clearly resolved. The density corresponding to one NBD is significantly smaller than that for the other, allowing us to confidently differentiate TAP1 from TAP2 (Fig. 2b) . Most importantly, we observe strong density corresponding to the functional region of ICP47, which reveals how this viral protein inhibits peptide translocation (Fig. 2b) .
The core region of TAP adopts an inverted 'V'-shaped structure, with the two TMDs making close contact on the side corresponding to the ER lumen and the NBDs separated from each other inside the cytosol (Fig. 2c ). Domain swapping of TM helices 4 and 5 across the TAP1/ TAP2 interface is a prominent structural feature (Fig. 2c) . Indeed, the overall structure of TAP is very similar to that of other ABC exporters, including the lipid flippase MsbA from Gram-negative bacteria 16 , the protein transporter PCAT1 from Gram-positive bacteria 17 , and the multidrug transporter P-glycoprotein in eukaryotes 18, 19 . Although these transporters recognize very different substrates, they must share a common evolutionary origin and a common mechanism for coupling ATP hydrolysis to substrate translocation.
No density was observed for the N-terminal TMD0 domain of both TAP1 and TAP2 subunits (Fig. 2) . Studies have shown that the TMD0s are essential to the assembly of the large peptide-loading complex 4,20 but dispensable in peptide translocation 4 . ICP47 inhibits both fulllength TAP and the core construct 4 . Our results indicate that in the absence of tapasin the two TMD0s are flexibly tethered to the core region of TAP.
Biochemical data and homology modelling suggest that the peptide translocation pathway lies at the interface of the two TMDs 21, 22 . Inside this pathway, we observe strong density consistent with the helixloop-helix structure of ICP47 (Figs 2b and 3a) . Guided by the NMR structure and secondary structure prediction 13 , we built residues 3-16 into the shorter helical density and residues 22-40 into the longer density (Fig. 3) . Additional density is packed along the cytosolic region of TAP2, into which we modelled residues 41-50. The carboxy (C)-terminal region, neither required for TAP inhibition nor conserved between HSV-1 and HSV-2 ( Fig. 3c) , is not resolved in the EM map, suggesting high mobility.
On the basis of this model, the N-terminal half of ICP47 forms a hairpin-like structure pinned against the inner surface of TAP2 TM helices 2, 3, 6 and TAP1 TM helix 4 (Fig. 3b ). The two helices of ICP47 run anti-parallel to each other, connected by a sharp turn at the top of the TM cavity. The extensive packing between TAP and ICP47 is consistent with the nanomolar affinity of ICP47, orders of magnitude higher than those of the substrate peptides 9,12 .
The potency of ICP47 appears to come from its helical hairpin structure, which provides a greater interface with TAP than a typical substrate. To test whether the flexibility of the connecting loop is important, we constructed a 'turn-to-helix' mutant by replacing residues 16-22 with alanine, which has the highest propensity to form an α-helix and thus would oppose (but not preclude) the formation of a turn. ICP47 activity was measured in human epithelial cells, in which cytosolic expression of ICP47 inhibits endogenous TAP and reduces the amount of MHC I molecules expressed on the cell surface. A green fluorescent protein (GFP) tag was fused to the C terminus of ICP47 as a marker to select for cells expressing similar amounts of ICP47. Consistent with the EM structure and previous mutagenesis data 11 , the 'turn-to-helix' mutant is much less potent than the wild-type construct. Specifically, mutant ICP47 reduced surface MHC I expression by only fivefold as opposed to a 20-fold reduction by wild-type ICP47 (Fig. 3d) .
Although ICP47 competes for the same binding site, we do not believe it mimics the substrate binding process. Unlike substrates, ICP47 inhibits rather than stimulates ATP hydrolysis 23 . Furthermore, in contrast to ICP47, which separates the two NBDs, substrate binding induces partial closure of the NBDs 24 . More recently, electron paramagnetic resonance studies showed that TAP binds its substrates in their extended conformations, comparable to how MHC I molecules present peptides 25 .
Comparison of our structure with the NMR structure of ICP47 (ref. 13) suggests that it undergoes major conformational changes upon association with TAP ( Fig. 4) . In isolation, the N-terminal two helices of ICP47 are flexibly linked and bind to the surface of the membrane at a slight tilt 13 . In the complex with TAP, ICP47 forms a straight hairpin and inserts perpendicularly into the membrane. Although exact determinations of the amino acid register cannot be made at the current resolution, the overall structure readily explains how ICP47 inhibits peptide transport into the ER. By plugging a long helical hairpin into the translocation pathway, ICP47 directly blocks substrates from binding. Furthermore, because ICP47 is too large to be transported by TAP, its high-affinity binding traps TAP in an inactive conformation. Like other ABC transporters, TAP functions by alternating between two major conformations, each exposing the translocation pathway to one side of the membrane (Fig. 4) . Binding of ICP47 stabilizes the inward-facing conformation, and thus prevents TAP from transitioning to an outward-facing state in which the NBDs form a closed dimer and the translocation pathway orientates towards the ER lumen (Fig. 4) .
In addition to viral inhibition discussed in this study, the structural basis of two cellular regulatory mechanisms has been elucidated [26] [27] [28] ; both are relevant to nutrient uptake in bacteria. As a classic example of carbon catabolite repression, when a preferred carbon source is available, bacteria suppress the uptake of maltose through direct binding of a regulatory protein to the maltose transporter 26 . Methionine TAP functions via alternating access, cycling between two major conformations (right). In the absence of substrates, the transporter rests in an inward-facing state in which the two NBDs are separated and the translocation pathway is exposed to the cytosol.
Upon association of substrates and ATP, the transporter undergoes a conformational change that reorients the TMDs and positions ATP at a closed NBD dimer interface for hydrolysis. ATP hydrolysis releases the substrate and resets the transporter to the resting state. ICP47 binds TAP stabilizing the inward-facing conformation (left).
and molybdate transporters offer another example 27, 28 . In both cases, at high intracellular concentration, the substrate binds and inhibits the corresponding transporter, a feedback mechanism that limits the amount of import into the cell 27, 28 . Unlike viral inhibition, both cellular inhibitions are allosteric and reversible, regulated by the metabolic state of the cells. One common theme among all these inhibition mechanisms is that the inhibitor binds and stabilizes the transporter in the inward-facing state, a conformation unable to hydrolyse ATP. We speculate that this strategy may be advantageous in preserving cellular energy sources. It is also possible that for most ABC transporters, the inward-facing state is most common and thus naturally targeted by regulators.
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